{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "28", "@year": "2024", "@timestamp": "2024-10-28T12:30:30.000030-04:00", "@month": "10"}, "ait:date-sort": {"@day": "01", "@year": "2017", "@month": "12"}}, "xocs:meta": {"xocs:funding-list": {"@pui-match": "primary", "@has-funding-info": "1", "xocs:funding": [{"xocs:funding-agency-matched-string": "Bristol-Myers Squibb", "xocs:funding-agency-acronym": "BMS", "xocs:funding-agency": "Bristol-Myers Squibb", "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100002491", "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"}, {"xocs:funding-agency-matched-string": "Pfizer", "xocs:funding-agency": "Pfizer", "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004319", "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"}, {"xocs:funding-agency-matched-string": "Novartis", "xocs:funding-agency": "Novartis", "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004336", "xocs:funding-agency-country": "http://sws.geonames.org/2658434/"}, {"xocs:funding-agency-matched-string": "Roche", "xocs:funding-agency": "Roche", "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004337", "xocs:funding-agency-country": "http://sws.geonames.org/2658434/"}, {"xocs:funding-agency-matched-string": "Ariad Pharmaceuticals", "xocs:funding-agency": "Ariad Pharmaceuticals", "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100006413", "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"}], "xocs:funding-addon-generated-timestamp": "2022-11-15T17:53:28.417Z", "xocs:funding-text": "S-H. Kim reports receiving speakers bureau honoraria from Dae-Woong Pharmaceutic Company. Y.R. Do reports receiving speakers bureau honoraria and reports receiving commercial research grants from Bristol-Myers Squibb and Novartis. C.W. Choi reports receiving commercial research grants from Il-Yang Pharm. D-Y. Kim reports receiving commercial research grants from Ilyang Co. and Roche. A.H. Reksodiputro reports receiving commercial research grants from Il-Yang Pharm. D-W. Kim reports receiving speakers bureau honoraria from Ilyang Co. and Novartis, is a consultant/advisory board member for Bristol-Myers Squibb, Ilyang Co., Novartis and Pfizer, and reports receiving commercial research grants from Ariad Co., Ilyang Co., Novartis and Pfizer. No potential conflicts of interest were disclosed by the other authors. Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.-Y. Kwak, S.-H. Kim, S.J. Oh, D.Y. Zang, H. Kim, J.-A. Kim, Y.R. Do, H.J. Kim, J.S. Park, C.W. Choi, W.S. Lee, Y.-C. Mun, J.S. Chung, H.-J. Shin, D.-Y. Kim, J. Park, C.W. Jung, U. Bunworasate, N.S. Comia, S. Jootar, P.B. Caguioa, S.-E. Lee, D.-W. Kim Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.-Y. Kwak, D.-Y. Kim, C.W. Jung, S.-E. Lee, D.-W. Kim Writing, review, and/or revision of the manuscript: J.-Y. Kwak, S.-H. Kim, D.Y. Zang, J.-A. Kim, Y.R. Do, C.W. Choi, W.S. Lee, Y.-C. Mun, J.H. Kong, J.S. Chung, D.-Y. Kim, J. Park, C.W. Jung, A.H. Reksodiputro, D.-W. Kim Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Jootar, A.H. Reksodiputro, D.-W. Kim Study supervision: A.H. Reksodiputro, D.-W. Kim We thank the patients and investigators for their participation in the trial and the Korea Leukemia Bank for biomaterial banking and analysis (NRF-2013M3A9B8031236). This study was funded by IL-YANG Pharmaceutical Co., Ltd, which also funded medical writing assistance. Professional medical writing and editorial assistance were provided by Lauren Gallagher, PhD, and Emilia Raszkiewicz of StemScientific, an Ashfield company, with funding from IL-YANG Pharmaceutical Co., Ltd. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.", "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"country": "South Korea", "@afid": "60016650", "@country": "kor", "city": "Jeonju", "organization": {"$": "Chonbuk National University Medical School and Hospital"}, "affiliation-id": {"@afid": "60016650"}}, "author": [{"ce:given-name": "Jae-Yong", "preferred-name": {"ce:given-name": "Jae Yong", "ce:initials": "J.Y.", "ce:surname": "Kwak", "ce:indexed-name": "Kwak J.Y."}, "@seq": "1", "ce:initials": "J.-Y.", "@_fa": "true", "@type": "auth", "ce:surname": "Kwak", "@auid": "57204796646", "ce:indexed-name": "Kwak J.-Y."}]}, {"affiliation": {"country": "South Korea", "@afid": "60016209", "@country": "kor", "city": "Busan", "organization": {"$": "Dong-A University Medical Center"}, "affiliation-id": {"@afid": "60016209"}}, "author": [{"ce:given-name": "Sung-Hyun", "preferred-name": {"ce:given-name": "Sung Hyun", "ce:initials": "S.H.", "ce:surname": "Kim", "ce:indexed-name": "Kim S.H."}, "@seq": "2", "ce:initials": "S.-H.", "@date-locked": "2021-04-12T05:10:36.194", "@_fa": "true", "@type": "auth", "ce:surname": "Kim", "@auid": "56547959500", "ce:indexed-name": "Kim S.-H."}]}, {"affiliation": {"country": "South Korea", "@afid": "60280060", "@country": "kor", "city": "Seoul", "organization": [{"$": "Kangbuk Samsung Hospital"}, {"$": "Sungkyunkwan University School of Medicine"}], "affiliation-id": [{"@afid": "60280060"}, {"@afid": "60016329"}]}, "author": [{"ce:given-name": "Suk Joong", "preferred-name": {"ce:given-name": "Suk Joong", "ce:initials": "S.J.", "ce:surname": "Oh", "ce:indexed-name": "Oh S.J."}, "@seq": "3", "ce:initials": "S.J.", "@_fa": "true", "@type": "auth", "ce:surname": "Oh", "@auid": "8920667400", "ce:indexed-name": "Oh S.J."}]}, {"affiliation": {"country": "South Korea", "@afid": "60018986", "@country": "kor", "city": "Anyang", "organization": {"$": "Hallym University Sacred Heart Hospital"}, "affiliation-id": {"@afid": "60018986"}}, "author": [{"ce:given-name": "Dae Young", "preferred-name": {"ce:given-name": "Dae Young", "ce:initials": "D.Y.", "ce:surname": "Zang", "ce:indexed-name": "Zang D.Y."}, "@seq": "4", "ce:initials": "D.Y.", "@_fa": "true", "@type": "auth", "ce:surname": "Zang", "@auid": "57216641597", "ce:indexed-name": "Zang D.Y."}]}, {"affiliation": {"country": "South Korea", "@afid": "60211748", "@country": "kor", "city": "Ulsan", "organization": {"$": "Ulsan University Hospital"}, "affiliation-id": {"@afid": "60211748"}}, "author": [{"ce:given-name": "Hawk", "preferred-name": {"ce:given-name": "Hawk", "ce:initials": "H.", "ce:surname": "Kim", "ce:indexed-name": "Kim H."}, "@seq": "5", "ce:initials": "H.", "@_fa": "true", "@type": "auth", "ce:surname": "Kim", "@auid": "57218435122", "ce:indexed-name": "Kim H."}]}, {"affiliation": {"country": "South Korea", "@afid": "60277007", "@country": "kor", "city": "Suwon", "organization": [{"$": "St. Vincent Hospital"}, {"$": "Catholic University of Korea"}], "affiliation-id": [{"@afid": "60277007"}, {"@afid": "60003087"}]}, "author": [{"ce:given-name": "Jeong-A", "preferred-name": {"ce:given-name": "Jeong A.", "ce:initials": "J.A.", "ce:surname": "Kim", "ce:indexed-name": "Kim J.A."}, "@seq": "6", "ce:initials": "J.-A.", "@date-locked": "2023-06-13T18:08:25.100", "@_fa": "true", "@type": "auth", "ce:surname": "Kim", "@auid": "57204030179", "ce:indexed-name": "Kim J.-A."}]}, {"affiliation": {"country": "South Korea", "@afid": "60094606", "@country": "kor", "city": "Daegu", "organization": [{"$": "Dongsan Medical Center"}, {"$": "Keimyung University"}], "affiliation-id": [{"@afid": "60094606"}, {"@afid": "60015576"}]}, "author": [{"ce:given-name": "Young Rok", "preferred-name": {"ce:given-name": "Young Rok", "ce:initials": "Y.R.", "ce:surname": "Do", "ce:indexed-name": "Do Y.R."}, "@seq": "7", "ce:initials": "Y.R.", "@_fa": "true", "@type": "auth", "ce:surname": "Do", "@auid": "8960168300", "ce:indexed-name": "Do Y.R."}]}, {"affiliation": {"country": "South Korea", "@afid": "60007215", "@country": "kor", "city": "Hwasun", "organization": [{"$": "Chonnam National University"}, {"$": "Hwasun Hospital"}], "affiliation-id": {"@afid": "60007215", "@dptid": "103400697"}, "@dptid": "103400697"}, "author": [{"ce:given-name": "Hyeoung Joon", "preferred-name": {"ce:given-name": "Hyeoung Joon", "ce:initials": "H.J.", "ce:surname": "Kim", "ce:indexed-name": "Kim H.J."}, "@seq": "8", "ce:initials": "H.J.", "@_fa": "true", "@type": "auth", "ce:surname": "Kim", "@auid": "7410127473", "ce:indexed-name": "Kim H.J."}]}, {"affiliation": {"country": "South Korea", "@afid": "60211621", "@country": "kor", "city": "Suwon", "organization": {"$": "Ajou University Hospital"}, "affiliation-id": {"@afid": "60211621"}}, "author": [{"ce:given-name": "Joon Seong", "preferred-name": {"ce:given-name": "Joon Seong", "ce:initials": "J.S.", "ce:surname": "Park", "ce:indexed-name": "Park J.S."}, "@seq": "9", "ce:initials": "J.S.", "@date-locked": "2019-06-13T08:44:42.946", "@_fa": "true", "@type": "auth", "ce:surname": "Park", "@auid": "56288590800", "ce:indexed-name": "Park J.S."}]}, {"affiliation": {"country": "South Korea", "@afid": "60212058", "@country": "kor", "city": "Seoul", "organization": [{"$": "Korea University"}, {"$": "Guro Hospital"}], "affiliation-id": [{"@afid": "60212058"}, {"@afid": "60005273"}]}, "author": [{"ce:given-name": "Chul Won", "preferred-name": {"ce:given-name": "Chul Won", "ce:initials": "C.W.", "ce:surname": "Choi", "ce:indexed-name": "Choi C.W."}, "@seq": "10", "ce:initials": "C.W.", "@date-locked": "2018-03-08T14:20:21.050", "@_fa": "true", "@type": "auth", "ce:surname": "Choi", "@auid": "13907063000", "ce:indexed-name": "Choi C.W."}]}, {"affiliation": {"country": "South Korea", "@afid": "60081368", "@country": "kor", "city": "Busan", "organization": {"$": "Inje University Busan Paik Hospital"}, "affiliation-id": {"@afid": "60081368"}}, "author": [{"ce:given-name": "Won Sik", "preferred-name": {"ce:given-name": "Won Sik", "ce:initials": "W.S.", "ce:surname": "Lee", "ce:indexed-name": "Lee W.S."}, "@seq": "11", "ce:initials": "W.S.", "@_fa": "true", "@type": "auth", "ce:surname": "Lee", "@auid": "55556573100", "ce:indexed-name": "Lee W.S."}]}, {"affiliation": {"country": "South Korea", "@afid": "60211798", "@country": "kor", "city": "Seoul", "organization": {"$": "Ewha Womans University Mokdong Hospital"}, "affiliation-id": {"@afid": "60211798"}}, "author": [{"ce:given-name": "Yeung-Chul", "preferred-name": {"ce:given-name": "Yeung Chul", "ce:initials": "Y.C.", "ce:surname": "Mun", "ce:indexed-name": "Mun Y.C."}, "@seq": "12", "ce:initials": "Y.-C.", "@date-locked": "2021-08-17T00:19:57.176", "@_fa": "true", "@type": "auth", "ce:surname": "Mun", "@auid": "7003363716", "ce:indexed-name": "Mun Y.-C."}]}, {"affiliation": {"country": "South Korea", "@afid": "60115404", "@country": "kor", "city": "Wonju", "organization": {"$": "Wonju Severance Christian Hospital"}, "affiliation-id": {"@afid": "60115404"}}, "author": [{"ce:given-name": "Jee Hyun", "preferred-name": {"ce:given-name": "Jee Hyun", "ce:initials": "J.H.", "ce:surname": "Kong", "ce:indexed-name": "Kong J.H."}, "@seq": "13", "ce:initials": "J.H.", "@date-locked": "2021-10-14T02:39:08.459", "@_fa": "true", "@type": "auth", "ce:surname": "Kong", "@auid": "56225377900", "ce:indexed-name": "Kong J.H."}]}, {"affiliation": {"country": "South Korea", "@afid": "60211908", "@country": "kor", "city": "Busan", "organization": {"$": "Pusan National University Hospital"}, "affiliation-id": {"@afid": "60211908"}}, "author": [{"ce:given-name": "Joo Seop", "preferred-name": {"ce:given-name": "Joo Seop", "ce:initials": "J.S.", "ce:surname": "Chung", "ce:indexed-name": "Chung J.S."}, "@seq": "14", "ce:initials": "J.S.", "@_fa": "true", "@type": "auth", "ce:surname": "Chung", "@auid": "34867913500", "ce:indexed-name": "Chung J.S."}, {"ce:given-name": "Ho-Jin", "preferred-name": {"ce:given-name": "Ho Jin", "ce:initials": "H.J.", "ce:surname": "Shin", "ce:indexed-name": "Shin H.J."}, "@seq": "15", "ce:initials": "H.-J.", "@_fa": "true", "@type": "auth", "ce:surname": "Shin", "@auid": "16239868400", "ce:indexed-name": "Shin H.-J."}]}, {"affiliation": {"country": "South Korea", "@afid": "60006240", "@country": "kor", "city": "Seoul", "organization": [{"$": "Asan Medical Center"}, {"$": "University of Ulsan College of Medicine"}], "affiliation-id": [{"@afid": "60006240"}, {"@afid": "60068691"}]}, "author": [{"ce:given-name": "Dae-Young", "preferred-name": {"ce:given-name": "Dae Young", "ce:initials": "D.Y.", "ce:surname": "Kim", "ce:indexed-name": "Kim D.Y."}, "@seq": "16", "ce:initials": "D.-Y.", "@_fa": "true", "@type": "auth", "ce:surname": "Kim", "@auid": "56955900700", "ce:indexed-name": "Kim D.-Y."}]}, {"affiliation": {"country": "South Korea", "@afid": "60199632", "@country": "kor", "city": "Seoul", "organization": {"$": "Gachon University Gil Medical Center"}, "affiliation-id": {"@afid": "60199632"}}, "author": [{"ce:given-name": "Jinny", "preferred-name": {"ce:given-name": "Jinny", "ce:initials": "J.", "ce:surname": "Park", "ce:indexed-name": "Park J."}, "@seq": "17", "ce:initials": "J.", "@_fa": "true", "@type": "auth", "ce:surname": "Park", "@auid": "56900190400", "ce:indexed-name": "Park J."}]}, {"affiliation": {"country": "South Korea", "@afid": "60016329", "@country": "kor", "city": "Seoul", "organization": [{"$": "Samsung Medical Center"}, {"$": "Sungkyunkwan University School of Medicine"}], "affiliation-id": [{"@afid": "60016329"}, {"@afid": "60020857"}]}, "author": [{"ce:given-name": "Chul Won", "preferred-name": {"ce:given-name": "Chul Won", "ce:initials": "C.W.", "ce:surname": "Jung", "ce:indexed-name": "Jung C.W."}, "@seq": "18", "ce:initials": "C.W.", "@date-locked": "2021-08-08T01:56:20.177", "@_fa": "true", "@type": "auth", "ce:surname": "Jung", "@auid": "56405934800", "ce:indexed-name": "Jung C.W."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "King Chulalongkorn Memorial Hospital"}, {"$": "Chulalongkorn University"}], "affiliation-id": [{"@afid": "60028190"}, {"@afid": "60022183"}]}, "author": [{"ce:given-name": "Udomsak", "preferred-name": {"ce:given-name": "Udomsak", "ce:initials": "U.", "ce:surname": "Bunworasate", "ce:indexed-name": "Bunworasate U."}, "@seq": "19", "ce:initials": "U.", "@_fa": "true", "@type": "auth", "ce:surname": "Bunworasate", "@auid": "6507403499", "ce:indexed-name": "Bunworasate U."}]}, {"affiliation": {"country": "Philippines", "@afid": "101869722", "@country": "phl", "city": "Lipa", "organization": {"$": "Mary Mediatrix Medical Center"}, "affiliation-id": {"@afid": "101869722"}}, "author": [{"ce:given-name": "Narcisa Sonia", "preferred-name": {"ce:given-name": "Narcisa Sonia", "ce:initials": "N.S.", "ce:surname": "Comia", "ce:indexed-name": "Comia N.S."}, "@seq": "20", "ce:initials": "N.S.", "@_fa": "true", "@type": "auth", "ce:surname": "Comia", "@auid": "57199170199", "ce:indexed-name": "Comia N.S."}]}, {"affiliation": {"country": "Thailand", "@afid": "60199578", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Faculty of Medicine"}, {"$": "Ramathibodi Hospital"}, {"$": "Mahidol University"}], "affiliation-id": [{"@afid": "60199578"}, {"@afid": "60015887"}, {"@afid": "60012718"}]}, "author": [{"ce:given-name": "Saengsuree", "preferred-name": {"ce:given-name": "Saengsuree", "ce:initials": "S.", "ce:surname": "Jootar", "ce:indexed-name": "Jootar S."}, "@seq": "21", "ce:initials": "S.", "@_fa": "true", "@type": "auth", "ce:surname": "Jootar", "@auid": "7003833820", "ce:indexed-name": "Jootar S."}]}, {"affiliation": {"country": "Indonesia", "@afid": "60069378", "@country": "idn", "city": "Jakarta", "organization": {"$": "Rumah Sakit Dr. Cipto Mangunkusumo Hospital"}, "affiliation-id": {"@afid": "60069378"}}, "author": [{"ce:given-name": "Arry Harryanto", "preferred-name": {"ce:given-name": "Arry Harryanto", "ce:initials": "A.H.", "ce:surname": "Reksodiputro", "ce:indexed-name": "Reksodiputro A.H."}, "@seq": "22", "ce:initials": "A.H.", "@_fa": "true", "@type": "auth", "ce:surname": "Reksodiputro", "@auid": "6507867066", "ce:indexed-name": "Reksodiputro A.H."}]}, {"affiliation": {"country": "Philippines", "@afid": "60071484", "@country": "phl", "city": "Manila", "organization": {"$": "St. Luke's Medical Center"}, "affiliation-id": {"@afid": "60071484"}}, "author": [{"ce:given-name": "Priscilla B.", "preferred-name": {"ce:given-name": "Priscilla B.", "ce:initials": "P.B.", "ce:surname": "Caguioa", "ce:indexed-name": "Caguioa P.B."}, "@seq": "23", "ce:initials": "P.B.", "@_fa": "true", "@type": "auth", "ce:surname": "Caguioa", "@auid": "6506598676", "ce:indexed-name": "Caguioa P.B."}]}, {"affiliation": {"country": "South Korea", "@afid": "60276990", "@country": "kor", "city": "Seoul", "organization": [{"$": "Seoul St. Mary's Hospital"}, {"$": "Leukemia Research Institute"}, {"$": "Catholic University of Korea"}], "affiliation-id": [{"@afid": "60276990", "@dptid": "129456731"}, {"@afid": "60003087"}], "@dptid": "129456731"}, "author": [{"ce:given-name": "Sung-Eun", "preferred-name": {"ce:given-name": "Sung Eun", "ce:initials": "S.E.", "ce:surname": "Lee", "ce:indexed-name": "Lee S.E."}, "@seq": "24", "ce:initials": "S.-E.", "@date-locked": "2021-06-25T01:16:37.419", "@_fa": "true", "@type": "auth", "ce:surname": "Lee", "@auid": "55156773300", "ce:indexed-name": "Lee S.-E."}, {"ce:given-name": "Dong-Wook", "preferred-name": {"ce:given-name": "Dong Wook", "ce:initials": "D.W.", "ce:surname": "Kim", "ce:indexed-name": "Kim D.W."}, "@seq": "25", "ce:initials": "D.-W.", "@date-locked": "2022-12-05T21:30:42.868", "@_fa": "true", "@type": "auth", "ce:surname": "Kim", "@auid": "57193414967", "ce:indexed-name": "Kim D.-W."}]}], "citation-title": "Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia", "abstracts": "\u00a92017 AACR.Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly diagnosed or with insufficient response to other TKIs. This study was conducted to evaluate the efficacy and safety of radotinib as first-line therapy for CML-CP. Experimental Design: This multinational, open-label study assigned patients (1:1:1) to one of two twice-daily radotinib doses, or imatinib daily. The primary endpoint was major molecular response (MMR) by 12 months. Results: Two hundred forty-one patients were randomized to receive radotinib 300 mg (n \u00bc 79) or 400 mg twice-daily (n \u00bc 81), or imatinib 400 mg daily (n \u00bc 81). MMR rates by 12 months were higher in patients receiving radotinib 300 mg (52%) or radotinib 400 mg twice-daily (46%) versus imatinib (30%; P \u00bc 0.0044 and P \u00bc 0.0342, respectively). Complete cytogenetic response (CCyR) rates by 12 months were higher for radotinib 300 mg (91%) versus imatinib (77%; P \u00bc 0.0120). Early molecular response at 3 months occurred in 86% and 87% of patients receiving radotinib 300 mg and radotinib 400 mg, respectively, and 71% of those receiving imatinib. By 12 months, no patients had progression to accelerated phase or blast crisis. Most adverse events were manageable with dose reduction. Conclusions: Radotinib demonstrated superiority over imatinib in CCyR and MMR in patients newly diagnosed with Philadelphia chromosome\u2013positive CML-CP. This trial was registered at www.clinicaltrials.gov as NCT01511289.", "correspondence": {"affiliation": {"country": "South Korea", "address-part": "222 Banpo-daero Seocho-gu", "postal-code": "137-701", "@country": "kor", "city": "Seoul", "organization": [{"$": "Seoul St. Mary's Hospital"}, {"$": "Leukemia Research Institute"}, {"$": "Catholic University of Korea"}]}, "person": {"ce:given-name": "Dong-Wook", "ce:initials": "D.-W.", "ce:surname": "Kim", "ce:indexed-name": "Kim D.-W."}}, "citation-info": {"citation-type": {"@code": "ar"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": {"@language": "English", "@xml:lang": "eng"}}, "source": {"website": {"ce:e-address": {"$": "http://clincancerres.aacrjournals.org/content/23/23/7180.full-text.pdf", "@type": "email"}}, "translated-sourcetitle": {"$": "Clinical Cancer Research", "@xml:lang": "eng"}, "volisspag": {"voliss": {"@volume": "23", "@issue": "23"}, "pagerange": {"@first": "7180", "@last": "7188"}}, "@type": "j", "sourcetitle": "Clinical Cancer Research", "publicationdate": {"month": "12", "year": "2017", "date-text": {"@xfab-added": "true", "$": "1 December 2017"}, "day": "01"}, "codencode": "CCREF", "sourcetitle-abbrev": "Clin. Cancer Res.", "@country": "usa", "issn": [{"$": "15573265", "@type": "electronic"}, {"$": "10780432", "@type": "print"}], "publicationyear": {"@first": "2017"}, "publisher": {"publishername": "American Association for Cancer Research Inc."}, "@srcid": "29263"}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "CABSCLASS", "classification": [{"classification-code": "86.9.1.2", "classification-description": "IMMUNOLOGY AND INFECTIOUS DISEASES; TUMOUR IMMUNOLOGY; Neoplasia of Immune System; Human studies"}, {"classification-code": "87.4.1", "classification-description": "CANCER RESEARCH; TREATMENT; Chemotherapy"}, {"classification-code": "87.5.26.1", "classification-description": "CANCER RESEARCH; CLINICAL INVESTIGATIONS BY ORGAN SITE; Haematologic Malignancies; Leukaemia"}]}, {"@type": "EMCLASS", "classification": [{"classification-code": "16", "classification-description": "Cancer"}, {"classification-code": "25", "classification-description": "Hematology"}, {"classification-code": "37", "classification-description": "Drug Literature Index"}, {"classification-code": "38", "classification-description": "Adverse Reactions Titles"}]}, {"@type": "ASJC", "classification": "2700"}, {"@type": "SUBJABBR", "classification": "MEDI"}]}, "chemicalgroup": {"chemicals": [{"@source": "esbd", "chemical": [{"cas-registry-number": [{"$": "152459-95-5"}, {"$": "220127-57-1"}], "chemical-name": "imatinib"}, {"cas-registry-number": "926037-48-1", "chemical-name": "radotinib"}]}, {"@source": "nlm", "chemical": [{"chemical-name": "4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide"}, {"chemical-name": "Benzamides"}, {"chemical-name": "Fusion Proteins, bcr-abl"}, {"chemical-name": "Imatinib Mesylate"}, {"chemical-name": "Protein Kinase Inhibitors"}, {"chemical-name": "Pyrazines"}]}]}}, "grantlist": {"@complete": "y", "grant-text": {"$": "S-H. Kim reports receiving speakers bureau honoraria from Dae-Woong Pharmaceutic Company. Y.R. Do reports receiving speakers bureau honoraria and reports receiving commercial research grants from Bristol-Myers Squibb and Novartis. C.W. Choi reports receiving commercial research grants from Il-Yang Pharm. D-Y. Kim reports receiving commercial research grants from Ilyang Co. and Roche. A.H. Reksodiputro reports receiving commercial research grants from Il-Yang Pharm. D-W. Kim reports receiving speakers bureau honoraria from Ilyang Co. and Novartis, is a consultant/advisory board member for Bristol-Myers Squibb, Ilyang Co., Novartis and Pfizer, and reports receiving commercial research grants from Ariad Co., Ilyang Co., Novartis and Pfizer. No potential conflicts of interest were disclosed by the other authors. Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.-Y. Kwak, S.-H. Kim, S.J. Oh, D.Y. Zang, H. Kim, J.-A. Kim, Y.R. Do, H.J. Kim, J.S. Park, C.W. Choi, W.S. Lee, Y.-C. Mun, J.S. Chung, H.-J. Shin, D.-Y. Kim, J. Park, C.W. Jung, U. Bunworasate, N.S. Comia, S. Jootar, P.B. Caguioa, S.-E. Lee, D.-W. Kim Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.-Y. Kwak, D.-Y. Kim, C.W. Jung, S.-E. Lee, D.-W. Kim Writing, review, and/or revision of the manuscript: J.-Y. Kwak, S.-H. Kim, D.Y. Zang, J.-A. Kim, Y.R. Do, C.W. Choi, W.S. Lee, Y.-C. Mun, J.H. Kong, J.S. Chung, D.-Y. Kim, J. Park, C.W. Jung, A.H. Reksodiputro, D.-W. Kim Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Jootar, A.H. Reksodiputro, D.-W. Kim Study supervision: A.H. Reksodiputro, D.-W. Kim We thank the patients and investigators for their participation in the trial and the Korea Leukemia Bank for biomaterial banking and analysis (NRF-2013M3A9B8031236). This study was funded by IL-YANG Pharmaceutical Co., Ltd, which also funded medical writing assistance. Professional medical writing and editorial assistance were provided by Lauren Gallagher, PhD, and Emilia Raszkiewicz of StemScientific, an Ashfield company, with funding from IL-YANG Pharmaceutical Co., Ltd. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.", "@xml:lang": "eng"}, "grant": [{"grant-agency": {"@iso-code": "usa", "$": "Ariad Pharmaceuticals"}, "grant-agency-id": "100006413"}, {"grant-acronym": "BMS", "grant-agency": {"@iso-code": "usa", "$": "Bristol-Myers Squibb"}, "grant-agency-id": "100002491"}, {"grant-agency": {"@iso-code": "che", "$": "Novartis"}, "grant-agency-id": "100004336"}, {"grant-agency": {"@iso-code": "usa", "$": "Pfizer"}, "grant-agency-id": "100004319"}, {"grant-agency": {"@iso-code": "che", "$": "Roche"}, "grant-agency-id": "100004337"}]}}, "item-info": {"copyright": {"$": "Copyright 2018 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, "external-source": "MEDLINE", "dbcollection": [{"$": "CABS"}, {"$": "EMBASE"}, {"$": "MEDL"}, {"$": "MOSYEA"}, {"$": "REAXYS"}, {"$": "REAXYSCAR"}, {"$": "RMC"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}], "history": {"date-created": {"@day": "19", "@year": "2018", "@timestamp": "BST 14:44:43", "@month": "07"}}, "itemidlist": {"itemid": [{"$": "619582378", "@idtype": "PUI"}, {"$": "2017386178", "@idtype": "CABS"}, {"$": "842968599", "@idtype": "CAR-ID"}, {"$": "20170871654", "@idtype": "EMBASE"}, {"$": "28939746", "@idtype": "MEDL"}, {"$": "2017140226", "@idtype": "MOSYEA"}, {"$": "2017272075", "@idtype": "REAXYS"}, {"$": "20172192019", "@idtype": "REAXYSCAR"}, {"$": "2017352911", "@idtype": "RMC"}, {"$": "20171204340", "@idtype": "SCOPUS"}, {"$": "85037616835", "@idtype": "SCP"}, {"$": "85037616835", "@idtype": "SGR"}, {"$": "623064757", "@idtype": "PUIsecondary"}], "ce:doi": "10.1158/1078-0432.CCR-17-0957"}}, "tail": {"bibliography": {"@refcount": "29", "reference": [{"ref-fulltext": "Nowell PC, Hungergord DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.", "@id": "1", "ref-info": {"ref-publicationyear": {"@first": "1960"}, "ref-title": {"ref-titletext": "A minute chromosome in human chronic granulocytic leukemia"}, "refd-itemidlist": {"itemid": {"$": "0000286732", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "132"}, "pagerange": {"@first": "1497"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.C.", "@_fa": "true", "ce:surname": "Nowell", "ce:indexed-name": "Nowell P.C."}, {"@seq": "2", "ce:initials": "D.A.", "@_fa": "true", "ce:surname": "Hungergord", "ce:indexed-name": "Hungergord D.A."}]}, "ref-sourcetitle": "Science"}}, {"ref-fulltext": "Rowley JD. A new consistent chromosomal abnormality in chronic mye-logenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature 1973;243:290\u20133.", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "1973"}, "ref-title": {"ref-titletext": "A new consistent chromosomal abnormality in chronic mye-logenous leukaemia identified by quinacrine fluorescence and Giemsa staining"}, "refd-itemidlist": {"itemid": {"$": "0015694748", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "243"}, "pagerange": {"@first": "290", "@last": "293"}}, "ref-text": "letter", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.D.", "@_fa": "true", "ce:surname": "Rowley", "ce:indexed-name": "Rowley J.D."}]}, "ref-sourcetitle": "Nature"}}, {"ref-fulltext": "Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984;37:1035\u201342.", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "1984"}, "ref-title": {"ref-titletext": "An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity"}, "refd-itemidlist": {"itemid": {"$": "0021674862", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "37"}, "pagerange": {"@first": "1035", "@last": "1042"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.B.", "@_fa": "true", "ce:surname": "Konopka", "ce:indexed-name": "Konopka J.B."}, {"@seq": "2", "ce:initials": "S.M.", "@_fa": "true", "ce:surname": "Watanabe", "ce:indexed-name": "Watanabe S.M."}, {"@seq": "3", "ce:initials": "O.N.", "@_fa": "true", "ce:surname": "Witte", "ce:indexed-name": "Witte O.N."}]}, "ref-sourcetitle": "Cell"}}, {"ref-fulltext": "Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013;122:872\u201384.", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "European LeukemiaNet recommendations for the management of chronic myeloid leukemia"}, "refd-itemidlist": {"itemid": {"$": "84881298446", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "122"}, "pagerange": {"@first": "872", "@last": "884"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Baccarani", "ce:indexed-name": "Baccarani M."}, {"@seq": "2", "ce:initials": "M.W.", "@_fa": "true", "ce:surname": "Deininger", "ce:indexed-name": "Deininger M.W."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Rosti", "ce:indexed-name": "Rosti G."}, {"@seq": "4", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Hochhaus", "ce:indexed-name": "Hochhaus A."}, {"@seq": "5", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Soverini", "ce:indexed-name": "Soverini S."}, {"@seq": "6", "ce:initials": "J.F.", "@_fa": "true", "ce:surname": "Apperley", "ce:indexed-name": "Apperley J.F."}], "et-al": null}, "ref-sourcetitle": "Blood"}}, {"ref-fulltext": "National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines (NCCN Guidelines). Chronic Myeloid Leukemia. Version 2.2017. Available from: http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf.", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2017"}, "ref-website": {"websitename": "National Comprehensive Cancer Network.", "ce:e-address": {"$": "http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf", "@type": "email"}}, "ref-title": {"ref-titletext": "National Comprehensive Cancer Network Guidelines (NCCN Guidelines)"}, "refd-itemidlist": {"itemid": {"$": "85037666047", "@idtype": "SGR"}}, "ref-text": "Version 2", "ref-sourcetitle": "Chronic Myeloid Leukemia"}}, {"ref-fulltext": "Hanfstein B, M\u00fcller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096\u2013102.", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)"}, "refd-itemidlist": {"itemid": {"$": "84865864744", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "26"}, "pagerange": {"@first": "2096", "@last": "2102"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Hanfstein", "ce:indexed-name": "Hanfstein B."}, {"@seq": "2", "ce:initials": "M.C.", "@_fa": "true", "ce:surname": "M\u00fcller", "ce:indexed-name": "Muller M.C."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Hehlmann", "ce:indexed-name": "Hehlmann R."}, {"@seq": "4", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Erben", "ce:indexed-name": "Erben P."}, {"@seq": "5", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Lauseker", "ce:indexed-name": "Lauseker M."}, {"@seq": "6", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Fabarius", "ce:indexed-name": "Fabarius A."}], "et-al": null}, "ref-sourcetitle": "Leukemia"}}, {"ref-fulltext": "Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 2013;121:2739\u201342.", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: Implications for early intervention strategies"}, "refd-itemidlist": {"itemid": {"$": "84878263769", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "121"}, "pagerange": {"@first": "2739", "@last": "2742"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Neelakantan", "ce:indexed-name": "Neelakantan P."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Gerrard", "ce:indexed-name": "Gerrard G."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Lucas", "ce:indexed-name": "Lucas C."}, {"@seq": "4", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Milojkovic", "ce:indexed-name": "Milojkovic D."}, {"@seq": "5", "ce:initials": "P.", "@_fa": "true", "ce:surname": "May", "ce:indexed-name": "May P."}, {"@seq": "6", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Wang", "ce:indexed-name": "Wang L."}], "et-al": null}, "ref-sourcetitle": "Blood"}}, {"ref-fulltext": "Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014;123:1353\u201360.", "@id": "8", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib"}, "refd-itemidlist": {"itemid": {"$": "84897007532", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "123"}, "pagerange": {"@first": "1353", "@last": "1360"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.P.", "@_fa": "true", "ce:surname": "Hughes", "ce:indexed-name": "Hughes T.P."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Saglio", "ce:indexed-name": "Saglio G."}, {"@seq": "3", "ce:initials": "H.M.", "@_fa": "true", "ce:surname": "Kantarjian", "ce:indexed-name": "Kantarjian H.M."}, {"@seq": "4", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Guilhot", "ce:indexed-name": "Guilhot F."}, {"@seq": "5", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Niederwieser", "ce:indexed-name": "Niederwieser D."}, {"@seq": "6", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Rosti", "ce:indexed-name": "Rosti G."}], "et-al": null}, "ref-sourcetitle": "Blood"}}, {"ref-fulltext": "Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u20acve chronic myeloid leukemia patients trial. J Clin Oncol 2016;34:2333\u201340.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-na\u20acve chronic myeloid leukemia patients trial"}, "refd-itemidlist": {"itemid": {"$": "84977485123", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "34"}, "pagerange": {"@first": "2333", "@last": "2340"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.E.", "@_fa": "true", "ce:surname": "Cortes", "ce:indexed-name": "Cortes J.E."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Saglio", "ce:indexed-name": "Saglio G."}, {"@seq": "3", "ce:initials": "H.M.", "@_fa": "true", "ce:surname": "Kantarjian", "ce:indexed-name": "Kantarjian H.M."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Baccarani", "ce:indexed-name": "Baccarani M."}, {"@seq": "5", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Mayer", "ce:indexed-name": "Mayer J."}, {"@seq": "6", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Boque", "ce:indexed-name": "Boque C."}], "et-al": null}, "ref-sourcetitle": "J Clin Oncol"}}, {"ref-fulltext": "Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs. imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016;30:1044\u201354.", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Long-term benefits and risks of frontline nilotinib vs. Imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial"}, "refd-itemidlist": {"itemid": {"$": "84959482245", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "30"}, "pagerange": {"@first": "1044", "@last": "1054"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Hochhaus", "ce:indexed-name": "Hochhaus A."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Saglio", "ce:indexed-name": "Saglio G."}, {"@seq": "3", "ce:initials": "T.P.", "@_fa": "true", "ce:surname": "Hughes", "ce:indexed-name": "Hughes T.P."}, {"@seq": "4", "ce:initials": "R.A.", "@_fa": "true", "ce:surname": "Larson", "ce:indexed-name": "Larson R.A."}, {"@seq": "5", "ce:initials": "D.W.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim D.W."}, {"@seq": "6", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Issaragrisil", "ce:indexed-name": "Issaragrisil S."}], "et-al": null}, "ref-sourcetitle": "Leukemia"}}, {"ref-fulltext": "Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica 2014;99:1191\u20136.", "@id": "11", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors"}, "refd-itemidlist": {"itemid": {"$": "84903650301", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "99"}, "pagerange": {"@first": "1191", "@last": "1196"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.H.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim S.H."}, {"@seq": "2", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Menon", "ce:indexed-name": "Menon H."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Jootar", "ce:indexed-name": "Jootar S."}, {"@seq": "4", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Saikia", "ce:indexed-name": "Saikia T."}, {"@seq": "5", "ce:initials": "J.Y.", "@_fa": "true", "ce:surname": "Kwak", "ce:indexed-name": "Kwak J.Y."}, {"@seq": "6", "ce:initials": "S.K.", "@_fa": "true", "ce:surname": "Sohn", "ce:indexed-name": "Sohn S.K."}], "et-al": null}, "ref-sourcetitle": "Haematologica"}}, {"ref-fulltext": "Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, O'Hare T. Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. Leukemia 2015;29:1939\u201342.", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1"}, "refd-itemidlist": {"itemid": {"$": "84940797179", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "29"}, "pagerange": {"@first": "1939", "@last": "1942"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.S.", "@_fa": "true", "ce:surname": "Zabriskie", "ce:indexed-name": "Zabriskie M.S."}, {"@seq": "2", "ce:initials": "N.A.", "@_fa": "true", "ce:surname": "Vellore", "ce:indexed-name": "Vellore N.A."}, {"@seq": "3", "ce:initials": "K.C.", "@_fa": "true", "ce:surname": "Gantz", "ce:indexed-name": "Gantz K.C."}, {"@seq": "4", "ce:initials": "M.W.", "@_fa": "true", "ce:surname": "Deininger", "ce:indexed-name": "Deininger M.W."}, {"@seq": "5", "ce:initials": "T.", "@_fa": "true", "ce:surname": "O'Hare", "ce:indexed-name": "O'Hare T."}]}, "ref-sourcetitle": "Leukemia"}}, {"ref-fulltext": "Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251\u20139.", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia"}, "refd-itemidlist": {"itemid": {"$": "77953691179", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "362"}, "pagerange": {"@first": "2251", "@last": "2259"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Saglio", "ce:indexed-name": "Saglio G."}, {"@seq": "2", "ce:initials": "D.W.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim D.W."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Issaragrisil", "ce:indexed-name": "Issaragrisil S."}, {"@seq": "4", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Le Coutre", "ce:indexed-name": "Le Coutre P."}, {"@seq": "5", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Etienne", "ce:indexed-name": "Etienne G."}, {"@seq": "6", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Lobo", "ce:indexed-name": "Lobo C."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260\u201370.", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia"}, "refd-itemidlist": {"itemid": {"$": "77953725855", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "362"}, "pagerange": {"@first": "2260", "@last": "2270"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Kantarjian", "ce:indexed-name": "Kantarjian H."}, {"@seq": "2", "ce:initials": "N.P.", "@_fa": "true", "ce:surname": "Shah", "ce:indexed-name": "Shah N.P."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Hochhaus", "ce:indexed-name": "Hochhaus A."}, {"@seq": "4", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Cortes", "ce:indexed-name": "Cortes J."}, {"@seq": "5", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Shah", "ce:indexed-name": "Shah S."}, {"@seq": "6", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Ayala", "ce:indexed-name": "Ayala M."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Chuah CT, Nakamae H, Shen ZX, Bradley-Garelik MB, Kim DW. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase. Leuk Lymphoma 2014;55:2093\u2013100.", "@id": "15", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase"}, "refd-itemidlist": {"itemid": {"$": "84906064878", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "55"}, "pagerange": {"@first": "2093", "@last": "2100"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.T.", "@_fa": "true", "ce:surname": "Chuah", "ce:indexed-name": "Chuah C.T."}, {"@seq": "2", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Nakamae", "ce:indexed-name": "Nakamae H."}, {"@seq": "3", "ce:initials": "Z.X.", "@_fa": "true", "ce:surname": "Shen", "ce:indexed-name": "Shen Z.X."}, {"@seq": "4", "ce:initials": "M.B.", "@_fa": "true", "ce:surname": "Bradley-Garelik", "ce:indexed-name": "Bradley-Garelik M.B."}, {"@seq": "5", "ce:initials": "D.W.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim D.W."}]}, "ref-sourcetitle": "Leuk Lymphoma"}}, {"ref-fulltext": "Noh H, Park MS, Kim SH, Oh SJ, Zang DY, Park HL, et al. Optimization of radotinib doses for the treatment of Asian patients with chronic myelog-enous leukemia based on dose-response relationship analyses. Leuk Lymphoma 2016;57:1856\u201364.", "@id": "16", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Optimization of radotinib doses for the treatment of Asian patients with chronic myelog-enous leukemia based on dose-response relationship analyses"}, "refd-itemidlist": {"itemid": {"$": "84949817054", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "57"}, "pagerange": {"@first": "1856", "@last": "1864"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Noh", "ce:indexed-name": "Noh H."}, {"@seq": "2", "ce:initials": "M.S.", "@_fa": "true", "ce:surname": "Park", "ce:indexed-name": "Park M.S."}, {"@seq": "3", "ce:initials": "S.H.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim S.H."}, {"@seq": "4", "ce:initials": "S.J.", "@_fa": "true", "ce:surname": "Oh", "ce:indexed-name": "Oh S.J."}, {"@seq": "5", "ce:initials": "D.Y.", "@_fa": "true", "ce:surname": "Zang", "ce:indexed-name": "Zang D.Y."}, {"@seq": "6", "ce:initials": "H.L.", "@_fa": "true", "ce:surname": "Park", "ce:indexed-name": "Park H.L."}], "et-al": null}, "ref-sourcetitle": "Leuk Lymphoma"}}, {"ref-fulltext": "Akard LP, Bixby D. Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase. Leuk Lymphoma 2016;57:1002\u201314.", "@id": "17", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase"}, "refd-itemidlist": {"itemid": {"$": "84953239054", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "57"}, "pagerange": {"@first": "1002", "@last": "1014"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.P.", "@_fa": "true", "ce:surname": "Akard", "ce:indexed-name": "Akard L.P."}, {"@seq": "2", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Bixby", "ce:indexed-name": "Bixby D."}]}, "ref-sourcetitle": "Leuk Lymphoma"}}, {"ref-fulltext": "Lee SE, Choi SY, Oh YJ, Kim SH, Song HY, Yoo HL, et al. Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia. Leuk Res 2015; 39:411\u20138.", "@id": "18", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia"}, "refd-itemidlist": {"itemid": {"$": "84925209944", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "39"}, "pagerange": {"@first": "411", "@last": "418"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.E.", "@_fa": "true", "ce:surname": "Lee", "ce:indexed-name": "Lee S.E."}, {"@seq": "2", "ce:initials": "S.Y.", "@_fa": "true", "ce:surname": "Choi", "ce:indexed-name": "Choi S.Y."}, {"@seq": "3", "ce:initials": "Y.J.", "@_fa": "true", "ce:surname": "Oh", "ce:indexed-name": "Oh Y.J."}, {"@seq": "4", "ce:initials": "S.H.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim S.H."}, {"@seq": "5", "ce:initials": "H.Y.", "@_fa": "true", "ce:surname": "Song", "ce:indexed-name": "Song H.Y."}, {"@seq": "6", "ce:initials": "H.L.", "@_fa": "true", "ce:surname": "Yoo", "ce:indexed-name": "Yoo H.L."}], "et-al": null}, "ref-sourcetitle": "Leuk Res"}}, {"ref-fulltext": "Horikoshi A, Takei K, Sawada S. Effects of lower dose of imatinib to CML patients. Leuk Res 2003;27:1167.", "@id": "19", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Effects of lower dose of imatinib to CML patients"}, "refd-itemidlist": {"itemid": {"$": "0042563130", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "27"}, "pagerange": {"@first": "1167"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Horikoshi", "ce:indexed-name": "Horikoshi A."}, {"@seq": "2", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Takei", "ce:indexed-name": "Takei K."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Sawada", "ce:indexed-name": "Sawada S."}]}, "ref-sourcetitle": "Leuk Res"}}, {"ref-fulltext": "Au WY, Caguoia PB, Chuah C, Hsu SC, Jootar S, Kim DW, et al. Chronic myeloid leukemia in Asia. Int J Hematol 2009;89:14\u201323.", "@id": "20", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Chronic myeloid leukemia in Asia"}, "refd-itemidlist": {"itemid": {"$": "67349123327", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "89"}, "pagerange": {"@first": "14", "@last": "23"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.Y.", "@_fa": "true", "ce:surname": "Au", "ce:indexed-name": "Au W.Y."}, {"@seq": "2", "ce:initials": "P.B.", "@_fa": "true", "ce:surname": "Caguoia", "ce:indexed-name": "Caguoia P.B."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Chuah", "ce:indexed-name": "Chuah C."}, {"@seq": "4", "ce:initials": "S.C.", "@_fa": "true", "ce:surname": "Hsu", "ce:indexed-name": "Hsu S.C."}, {"@seq": "5", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Jootar", "ce:indexed-name": "Jootar S."}, {"@seq": "6", "ce:initials": "D.W.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim D.W."}], "et-al": null}, "ref-sourcetitle": "Int J Hematol"}}, {"ref-fulltext": "Kawaguchi T, Hamada A, Hirayama C, Nakashima R, Nambu T, Yamakawa Y, et al. Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. Int J Hematol 2009;89:642\u20138.", "@id": "21", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia"}, "refd-itemidlist": {"itemid": {"$": "67749101106", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "89"}, "pagerange": {"@first": "642", "@last": "648"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Kawaguchi", "ce:indexed-name": "Kawaguchi T."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Hamada", "ce:indexed-name": "Hamada A."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Hirayama", "ce:indexed-name": "Hirayama C."}, {"@seq": "4", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Nakashima", "ce:indexed-name": "Nakashima R."}, {"@seq": "5", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Nambu", "ce:indexed-name": "Nambu T."}, {"@seq": "6", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Yamakawa", "ce:indexed-name": "Yamakawa Y."}], "et-al": null}, "ref-sourcetitle": "Int J Hematol"}}, {"ref-fulltext": "Kim DW, Goh YT, Hsiao HH, Caguioa PB, Kim D, Kim WS, et al. Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia. Int J Hematol 2009;89:664\u201372.", "@id": "22", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia"}, "refd-itemidlist": {"itemid": {"$": "67749111388", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "89"}, "pagerange": {"@first": "664", "@last": "672"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.W.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim D.W."}, {"@seq": "2", "ce:initials": "Y.T.", "@_fa": "true", "ce:surname": "Goh", "ce:indexed-name": "Goh Y.T."}, {"@seq": "3", "ce:initials": "H.H.", "@_fa": "true", "ce:surname": "Hsiao", "ce:indexed-name": "Hsiao H.H."}, {"@seq": "4", "ce:initials": "P.B.", "@_fa": "true", "ce:surname": "Caguioa", "ce:indexed-name": "Caguioa P.B."}, {"@seq": "5", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim D."}, {"@seq": "6", "ce:initials": "W.S.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim W.S."}], "et-al": null}, "ref-sourcetitle": "Int J Hematol"}}, {"ref-fulltext": "Wang J, Shen ZX, Saglio G, Jin J, Huang H, Hu Y, et al. Phase 3 study of nilotinib vs. imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood 2015;125: 2771\u20138.", "@id": "23", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Phase 3 study of nilotinib vs. Imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina"}, "refd-itemidlist": {"itemid": {"$": "84929494071", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "125"}, "pagerange": {"@first": "2771", "@last": "2778"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Wang", "ce:indexed-name": "Wang J."}, {"@seq": "2", "ce:initials": "Z.X.", "@_fa": "true", "ce:surname": "Shen", "ce:indexed-name": "Shen Z.X."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Saglio", "ce:indexed-name": "Saglio G."}, {"@seq": "4", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Jin", "ce:indexed-name": "Jin J."}, {"@seq": "5", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Huang", "ce:indexed-name": "Huang H."}, {"@seq": "6", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Hu", "ce:indexed-name": "Hu Y."}], "et-al": null}, "ref-sourcetitle": "Blood"}}, {"ref-fulltext": "Noh H, Jung SY, Kwak J-Y, Kim S-H, Joong OS, Zang DY, et al. Impact of body weight adjusted dose on efficacy and safety of radotinib in chronic myeloid leukemia. Blood 2016;128:3086.", "@id": "24", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Impact of body weight adjusted dose on efficacy and safety of radotinib in chronic myeloid leukemia"}, "refd-itemidlist": {"itemid": {"$": "85037651461", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "128"}, "pagerange": {"@first": "3086"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Noh", "ce:indexed-name": "Noh H."}, {"@seq": "2", "ce:initials": "S.Y.", "@_fa": "true", "ce:surname": "Jung", "ce:indexed-name": "Jung S.Y."}, {"@seq": "3", "ce:initials": "J.-Y.", "@_fa": "true", "ce:surname": "Kwak", "ce:indexed-name": "Kwak J.-Y."}, {"@seq": "4", "ce:initials": "S.-H.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim S.-H."}, {"@seq": "5", "ce:initials": "O.S.", "@_fa": "true", "ce:surname": "Joong", "ce:indexed-name": "Joong O.S."}, {"@seq": "6", "ce:initials": "D.Y.", "@_fa": "true", "ce:surname": "Zang", "ce:indexed-name": "Zang D.Y."}], "et-al": null}, "ref-sourcetitle": "Blood"}}, {"ref-fulltext": "Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022\u20138.", "@id": "25", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study"}, "refd-itemidlist": {"itemid": {"$": "43249083718", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "111"}, "pagerange": {"@first": "4022", "@last": "4028"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.A.", "@_fa": "true", "ce:surname": "Larson", "ce:indexed-name": "Larson R.A."}, {"@seq": "2", "ce:initials": "B.J.", "@_fa": "true", "ce:surname": "Druker", "ce:indexed-name": "Druker B.J."}, {"@seq": "3", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Guilhot", "ce:indexed-name": "Guilhot F."}, {"@seq": "4", "ce:initials": "S.G.", "@_fa": "true", "ce:surname": "O'Brien", "ce:indexed-name": "O'Brien S.G."}, {"@seq": "5", "ce:initials": "G.J.", "@_fa": "true", "ce:surname": "Riviere", "ce:indexed-name": "Riviere G.J."}, {"@seq": "6", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Krahnke", "ce:indexed-name": "Krahnke T."}], "et-al": null}, "ref-sourcetitle": "Blood"}}, {"ref-fulltext": "Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496\u20139.", "@id": "26", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia"}, "refd-itemidlist": {"itemid": {"$": "34147174980", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "109"}, "pagerange": {"@first": "3496", "@last": "3499"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Picard", "ce:indexed-name": "Picard S."}, {"@seq": "2", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Titier", "ce:indexed-name": "Titier K."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Etienne", "ce:indexed-name": "Etienne G."}, {"@seq": "4", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Teilhet", "ce:indexed-name": "Teilhet E."}, {"@seq": "5", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Ducint", "ce:indexed-name": "Ducint D."}, {"@seq": "6", "ce:initials": "M.A.", "@_fa": "true", "ce:surname": "Bernard", "ce:indexed-name": "Bernard M.A."}], "et-al": null}, "ref-sourcetitle": "Blood"}}, {"ref-fulltext": "Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph \u00fe chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol 2012;68:723\u201333.", "@id": "27", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph \u00fe chronic myeloid leukemia in chronic phase"}, "refd-itemidlist": {"itemid": {"$": "84864285497", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "68"}, "pagerange": {"@first": "723", "@last": "733"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.A.", "@_fa": "true", "ce:surname": "Larson", "ce:indexed-name": "Larson R.A."}, {"@seq": "2", "ce:initials": "O.Q.", "@_fa": "true", "ce:surname": "Yin", "ce:indexed-name": "Yin O.Q."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Hochhaus", "ce:indexed-name": "Hochhaus A."}, {"@seq": "4", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Saglio", "ce:indexed-name": "Saglio G."}, {"@seq": "5", "ce:initials": "R.E.", "@_fa": "true", "ce:surname": "Clark", "ce:indexed-name": "Clark R.E."}, {"@seq": "6", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Nakamae", "ce:indexed-name": "Nakamae H."}], "et-al": null}, "ref-sourcetitle": "Eur J Clin Pharmacol"}}, {"ref-fulltext": "Wang X, Hochhaus A, Kantarjian HM, Agrawal S, Roy A, Pfister M, et al. Dasatinib pharmacokinetics and exposure-response (E-R): relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML) [abstract]. J Clin Oncol 26:15s,2008(suppl; abstr 3590).", "@id": "28", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML)"}, "refd-itemidlist": {"itemid": [{"$": "3590", "@idtype": "ABSTRACTNUMBER"}, {"$": "55949102580", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "26"}, "pagerange": {"@first": "15s"}}, "ref-text": "abstract", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Wang", "ce:indexed-name": "Wang X."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Hochhaus", "ce:indexed-name": "Hochhaus A."}, {"@seq": "3", "ce:initials": "H.M.", "@_fa": "true", "ce:surname": "Kantarjian", "ce:indexed-name": "Kantarjian H.M."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Agrawal", "ce:indexed-name": "Agrawal S."}, {"@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Roy", "ce:indexed-name": "Roy A."}, {"@seq": "6", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Pfister", "ce:indexed-name": "Pfister M."}], "et-al": null}, "ref-sourcetitle": "J Clin Oncol"}}, {"ref-fulltext": "Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553\u201361.", "@id": "29", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib"}, "refd-itemidlist": {"itemid": {"$": "79953880772", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "103"}, "pagerange": {"@first": "553", "@last": "561"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Gambacorti-Passerini", "ce:indexed-name": "Gambacorti-Passerini C."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Antolini", "ce:indexed-name": "Antolini L."}, {"@seq": "3", "ce:initials": "F.X.", "@_fa": "true", "ce:surname": "Mahon", "ce:indexed-name": "Mahon F.X."}, {"@seq": "4", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Guilhot", "ce:indexed-name": "Guilhot F."}, {"@seq": "5", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Deininger", "ce:indexed-name": "Deininger M."}, {"@seq": "6", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Fava", "ce:indexed-name": "Fava C."}], "et-al": null}, "ref-sourcetitle": "J Natl Cancer Inst"}}]}}}}, "affiliation": [{"affiliation-city": "Jongno-gu", "@id": "60280060", "affilname": "Kangbuk Samsung Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60280060", "affiliation-country": "South Korea"}, {"affiliation-city": "Suwon", "@id": "60277007", "affilname": "The Catholic University of Korea, St. Vincent's Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60277007", "affiliation-country": "South Korea"}, {"affiliation-city": "Seoul", "@id": "60276990", "affilname": "The Catholic University of Korea Seoul St. Mary's Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60276990", "affiliation-country": "South Korea"}, {"affiliation-city": "Seoul", "@id": "60212058", "affilname": "Korea University Guro Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60212058", "affiliation-country": "South Korea"}, {"affiliation-city": "Busan", "@id": "60211908", "affilname": "Pusan National University Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60211908", "affiliation-country": "South Korea"}, {"affiliation-city": "Seoul", "@id": "60211798", "affilname": "Ewha Womans University Mokdong Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60211798", "affiliation-country": "South Korea"}, {"affiliation-city": "Ulsan", "@id": "60211748", "affilname": "Ulsan University Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60211748", "affiliation-country": "South Korea"}, {"affiliation-city": "Suwon", "@id": "60211621", "affilname": "Ajou University Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60211621", "affiliation-country": "South Korea"}, {"affiliation-city": "Seongnam", "@id": "60199632", "affilname": "Gachon University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199632", "affiliation-country": "South Korea"}, {"affiliation-city": "Bangkok", "@id": "60199578", "affilname": "Ramathibodi Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578", "affiliation-country": "Thailand"}, {"affiliation-city": "Wonju", "@id": "60115404", "affilname": "Wonju Severance Christian Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60115404", "affiliation-country": "South Korea"}, {"affiliation-city": "Daegu", "@id": "60094606", "affilname": "Keimyung University, Dongsan Medical Center", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60094606", "affiliation-country": "South Korea"}, {"affiliation-city": "Seoul", "@id": "60081368", "affilname": "Inje University Paik Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60081368", "affiliation-country": "South Korea"}, {"affiliation-city": "Quezon City", "@id": "60071484", "affilname": "St. Luke's Medical Center Quezon City", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071484", "affiliation-country": "Philippines"}, {"affiliation-city": "Central Jakarta", "@id": "60069378", "affilname": "Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069378", "affiliation-country": "Indonesia"}, {"affiliation-city": "Bangkok", "@id": "60028190", "affilname": "Chulalongkorn University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190", "affiliation-country": "Thailand"}, {"affiliation-city": "Chuncheon", "@id": "60018986", "affilname": "Hallym University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018986", "affiliation-country": "South Korea"}, {"affiliation-city": "Jeonju", "@id": "60016650", "affilname": "Jeonbuk National University, School of Medicine", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016650", "affiliation-country": "South Korea"}, {"affiliation-city": "Suwon", "@id": "60016329", "affilname": "SKKU School of Medicine", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016329", "affiliation-country": "South Korea"}, {"affiliation-city": "Busan", "@id": "60016209", "affilname": "Dong-A University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016209", "affiliation-country": "South Korea"}, {"affiliation-city": "Gwangju", "@id": "60007215", "affilname": "Chonnam National University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007215", "affiliation-country": "South Korea"}, {"affiliation-city": "Seoul", "@id": "60006240", "affilname": "University of Ulsan College of Medicine", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006240", "affiliation-country": "South Korea"}, {"affiliation-city": "Batangas", "@id": "101869722", "affilname": "Mary Mediatrix Medical Center", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101869722", "affiliation-country": "Philippines"}], "coredata": {"srctype": "j", "eid": "2-s2.0-85037616835", "dc:description": "Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly diagnosed or with insufficient response to other TKIs. This study was conducted to evaluate the efficacy and safety of radotinib as first-line therapy for CML-CP. Experimental Design: This multinational, open-label study assigned patients (1:1:1) to one of two twice-daily radotinib doses, or imatinib daily. The primary endpoint was major molecular response (MMR) by 12 months. Results: Two hundred forty-one patients were randomized to receive radotinib 300 mg (n \u00bc 79) or 400 mg twice-daily (n \u00bc 81), or imatinib 400 mg daily (n \u00bc 81). MMR rates by 12 months were higher in patients receiving radotinib 300 mg (52%) or radotinib 400 mg twice-daily (46%) versus imatinib (30%; P \u00bc 0.0044 and P \u00bc 0.0342, respectively). Complete cytogenetic response (CCyR) rates by 12 months were higher for radotinib 300 mg (91%) versus imatinib (77%; P \u00bc 0.0120). Early molecular response at 3 months occurred in 86% and 87% of patients receiving radotinib 300 mg and radotinib 400 mg, respectively, and 71% of those receiving imatinib. By 12 months, no patients had progression to accelerated phase or blast crisis. Most adverse events were manageable with dose reduction. Conclusions: Radotinib demonstrated superiority over imatinib in CCyR and MMR in patients newly diagnosed with Philadelphia chromosome\u2013positive CML-CP. This trial was registered at www.clinicaltrials.gov as NCT01511289.", "pubmed-id": "28939746", "prism:coverDate": "2017-12-01", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85037616835", "dc:creator": {"author": [{"ce:given-name": "Jae-Yong", "preferred-name": {"ce:given-name": "Jae Yong", "ce:initials": "J.Y.", "ce:surname": "Kwak", "ce:indexed-name": "Kwak J.Y."}, "@seq": "1", "ce:initials": "J.-Y.", "@_fa": "true", "affiliation": {"@id": "60016650", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016650"}, "ce:surname": "Kwak", "@auid": "57204796646", "author-url": "https://api.elsevier.com/content/author/author_id/57204796646", "ce:indexed-name": "Kwak J.-Y."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/85037616835"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85037616835&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85037616835&origin=inward"}], "source-id": "29263", "citedby-count": "58", "prism:volume": "23", "subtype": "ar", "dc:title": "Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia", "openaccess": "1", "prism:issn": "15573265 10780432", "publishercopyright": "\u00a92017 AACR.", "prism:issueIdentifier": "23", "subtypeDescription": "Article", "prism:publicationName": "Clinical Cancer Research", "prism:pageRange": "7180-7188", "prism:endingPage": "7188", "openaccessFlag": "true", "prism:doi": "10.1158/1078-0432.CCR-17-0957", "prism:startingPage": "7180", "dc:identifier": "SCOPUS_ID:85037616835", "dc:publisher": "American Association for Cancer Research Inc."}, "idxterms": {"mainterm": [{"$": "Adult", "@weight": "b", "@candidate": "n"}, {"$": "Benzamides", "@weight": "b", "@candidate": "n"}, {"$": "Drug Administration Schedule", "@weight": "b", "@candidate": "n"}, {"$": "Female", "@weight": "b", "@candidate": "n"}, {"$": "Fusion Proteins, bcr-abl", "@weight": "b", "@candidate": "n"}, {"$": "Humans", "@weight": "b", "@candidate": "n"}, {"$": "Imatinib Mesylate", "@weight": "b", "@candidate": "n"}, {"$": "Leukemia, Myeloid, Chronic-Phase", "@weight": "b", "@candidate": "n"}, {"$": "Male", "@weight": "b", "@candidate": "n"}, {"$": "Middle Aged", "@weight": "b", "@candidate": "n"}, {"$": "Neutropenia", "@weight": "b", "@candidate": "n"}, {"$": "Protein Kinase Inhibitors", "@weight": "b", "@candidate": "n"}, {"$": "Pyrazines", "@weight": "b", "@candidate": "n"}, {"$": "Remission Induction", "@weight": "b", "@candidate": "n"}, {"$": "Thrombocytopenia", "@weight": "b", "@candidate": "n"}, {"$": "Treatment Outcome", "@weight": "b", "@candidate": "n"}]}, "language": {"@xml:lang": "eng"}, "authkeywords": null, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Medicine (all)", "@code": "2700", "@abbrev": "MEDI"}]}, "authors": {"author": [{"ce:given-name": "Jae-Yong", "preferred-name": {"ce:given-name": "Jae Yong", "ce:initials": "J.Y.", "ce:surname": "Kwak", "ce:indexed-name": "Kwak J.Y."}, "@seq": "1", "ce:initials": "J.-Y.", "@_fa": "true", "affiliation": {"@id": "60016650", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016650"}, "ce:surname": "Kwak", "@auid": "57204796646", "author-url": "https://api.elsevier.com/content/author/author_id/57204796646", "ce:indexed-name": "Kwak J.-Y."}, {"ce:given-name": "Sung-Hyun", "preferred-name": {"ce:given-name": "Sung Hyun", "ce:initials": "S.H.", "ce:surname": "Kim", "ce:indexed-name": "Kim S.H."}, "@seq": "2", "ce:initials": "S.-H.", "@_fa": "true", "affiliation": {"@id": "60016209", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016209"}, "ce:surname": "Kim", "@auid": "56547959500", "author-url": "https://api.elsevier.com/content/author/author_id/56547959500", "ce:indexed-name": "Kim S.-H."}, {"ce:given-name": "Suk Joong", "preferred-name": {"ce:given-name": "Suk Joong", "ce:initials": "S.J.", "ce:surname": "Oh", "ce:indexed-name": "Oh S.J."}, "@seq": "3", "ce:initials": "S.J.", "@_fa": "true", "affiliation": {"@id": "60280060", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60280060"}, "ce:surname": "Oh", "@auid": "8920667400", "author-url": "https://api.elsevier.com/content/author/author_id/8920667400", "ce:indexed-name": "Oh S.J."}, {"ce:given-name": "Dae Young", "preferred-name": {"ce:given-name": "Dae Young", "ce:initials": "D.Y.", "ce:surname": "Zang", "ce:indexed-name": "Zang D.Y."}, "@seq": "4", "ce:initials": "D.Y.", "@_fa": "true", "affiliation": {"@id": "60018986", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018986"}, "ce:surname": "Zang", "@auid": "57216641597", "author-url": "https://api.elsevier.com/content/author/author_id/57216641597", "ce:indexed-name": "Zang D.Y."}, {"ce:given-name": "Hawk", "preferred-name": {"ce:given-name": "Hawk", "ce:initials": "H.", "ce:surname": "Kim", "ce:indexed-name": "Kim H."}, "@seq": "5", "ce:initials": "H.", "@_fa": "true", "affiliation": {"@id": "60211748", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60211748"}, "ce:surname": "Kim", "@auid": "57218435122", "author-url": "https://api.elsevier.com/content/author/author_id/57218435122", "ce:indexed-name": "Kim H."}, {"ce:given-name": "Jeong-A", "preferred-name": {"ce:given-name": "Jeong A.", "ce:initials": "J.A.", "ce:surname": "Kim", "ce:indexed-name": "Kim J.A."}, "@seq": "6", "ce:initials": "J.-A.", "@_fa": "true", "affiliation": {"@id": "60277007", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60277007"}, "ce:surname": "Kim", "@auid": "57204030179", "author-url": "https://api.elsevier.com/content/author/author_id/57204030179", "ce:indexed-name": "Kim J.-A."}, {"ce:given-name": "Young Rok", "preferred-name": {"ce:given-name": "Young Rok", "ce:initials": "Y.R.", "ce:surname": "Do", "ce:indexed-name": "Do Y.R."}, "@seq": "7", "ce:initials": "Y.R.", "@_fa": "true", "affiliation": {"@id": "60094606", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60094606"}, "ce:surname": "Do", "@auid": "8960168300", "author-url": "https://api.elsevier.com/content/author/author_id/8960168300", "ce:indexed-name": "Do Y.R."}, {"ce:given-name": "Hyeoung Joon", "preferred-name": {"ce:given-name": "Hyeoung Joon", "ce:initials": "H.J.", "ce:surname": "Kim", "ce:indexed-name": "Kim H.J."}, "@seq": "8", "ce:initials": "H.J.", "@_fa": "true", "affiliation": {"@id": "60007215", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007215"}, "ce:surname": "Kim", "@auid": "7410127473", "author-url": "https://api.elsevier.com/content/author/author_id/7410127473", "ce:indexed-name": "Kim H.J."}, {"ce:given-name": "Joon Seong", "preferred-name": {"ce:given-name": "Joon Seong", "ce:initials": "J.S.", "ce:surname": "Park", "ce:indexed-name": "Park J.S."}, "@seq": "9", "ce:initials": "J.S.", "@_fa": "true", "affiliation": {"@id": "60211621", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60211621"}, "ce:surname": "Park", "@auid": "56288590800", "author-url": "https://api.elsevier.com/content/author/author_id/56288590800", "ce:indexed-name": "Park J.S."}, {"ce:given-name": "Chul Won", "preferred-name": {"ce:given-name": "Chul Won", "ce:initials": "C.W.", "ce:surname": "Choi", "ce:indexed-name": "Choi C.W."}, "@seq": "10", "ce:initials": "C.W.", "@_fa": "true", "affiliation": {"@id": "60212058", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60212058"}, "ce:surname": "Choi", "@auid": "13907063000", "author-url": "https://api.elsevier.com/content/author/author_id/13907063000", "ce:indexed-name": "Choi C.W."}, {"ce:given-name": "Won Sik", "preferred-name": {"ce:given-name": "Won Sik", "ce:initials": "W.S.", "ce:surname": "Lee", "ce:indexed-name": "Lee W.S."}, "@seq": "11", "ce:initials": "W.S.", "@_fa": "true", "affiliation": {"@id": "60081368", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60081368"}, "ce:surname": "Lee", "@auid": "55556573100", "author-url": "https://api.elsevier.com/content/author/author_id/55556573100", "ce:indexed-name": "Lee W.S."}, {"ce:given-name": "Yeung-Chul", "preferred-name": {"ce:given-name": "Yeung Chul", "ce:initials": "Y.C.", "ce:surname": "Mun", "ce:indexed-name": "Mun Y.C."}, "@seq": "12", "ce:initials": "Y.-C.", "@_fa": "true", "affiliation": {"@id": "60211798", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60211798"}, "ce:surname": "Mun", "@auid": "7003363716", "author-url": "https://api.elsevier.com/content/author/author_id/7003363716", "ce:indexed-name": "Mun Y.-C."}, {"ce:given-name": "Jee Hyun", "preferred-name": {"ce:given-name": "Jee Hyun", "ce:initials": "J.H.", "ce:surname": "Kong", "ce:indexed-name": "Kong J.H."}, "@seq": "13", "ce:initials": "J.H.", "@_fa": "true", "affiliation": {"@id": "60115404", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60115404"}, "ce:surname": "Kong", "@auid": "56225377900", "author-url": "https://api.elsevier.com/content/author/author_id/56225377900", "ce:indexed-name": "Kong J.H."}, {"ce:given-name": "Joo Seop", "preferred-name": {"ce:given-name": "Joo Seop", "ce:initials": "J.S.", "ce:surname": "Chung", "ce:indexed-name": "Chung J.S."}, "@seq": "14", "ce:initials": "J.S.", "@_fa": "true", "affiliation": {"@id": "60211908", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60211908"}, "ce:surname": "Chung", "@auid": "34867913500", "author-url": "https://api.elsevier.com/content/author/author_id/34867913500", "ce:indexed-name": "Chung J.S."}, {"ce:given-name": "Ho-Jin", "preferred-name": {"ce:given-name": "Ho Jin", "ce:initials": "H.J.", "ce:surname": "Shin", "ce:indexed-name": "Shin H.J."}, "@seq": "15", "ce:initials": "H.-J.", "@_fa": "true", "affiliation": {"@id": "60211908", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60211908"}, "ce:surname": "Shin", "@auid": "16239868400", "author-url": "https://api.elsevier.com/content/author/author_id/16239868400", "ce:indexed-name": "Shin H.-J."}, {"ce:given-name": "Dae-Young", "preferred-name": {"ce:given-name": "Dae Young", "ce:initials": "D.Y.", "ce:surname": "Kim", "ce:indexed-name": "Kim D.Y."}, "@seq": "16", "ce:initials": "D.-Y.", "@_fa": "true", "affiliation": {"@id": "60006240", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006240"}, "ce:surname": "Kim", "@auid": "56955900700", "author-url": "https://api.elsevier.com/content/author/author_id/56955900700", "ce:indexed-name": "Kim D.-Y."}, {"ce:given-name": "Jinny", "preferred-name": {"ce:given-name": "Jinny", "ce:initials": "J.", "ce:surname": "Park", "ce:indexed-name": "Park J."}, "@seq": "17", "ce:initials": "J.", "@_fa": "true", "affiliation": {"@id": "60199632", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199632"}, "ce:surname": "Park", "@auid": "56900190400", "author-url": "https://api.elsevier.com/content/author/author_id/56900190400", "ce:indexed-name": "Park J."}, {"ce:given-name": "Chul Won", "preferred-name": {"ce:given-name": "Chul Won", "ce:initials": "C.W.", "ce:surname": "Jung", "ce:indexed-name": "Jung C.W."}, "@seq": "18", "ce:initials": "C.W.", "@_fa": "true", "affiliation": {"@id": "60016329", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016329"}, "ce:surname": "Jung", "@auid": "56405934800", "author-url": "https://api.elsevier.com/content/author/author_id/56405934800", "ce:indexed-name": "Jung C.W."}, {"ce:given-name": "Udomsak", "preferred-name": {"ce:given-name": "Udomsak", "ce:initials": "U.", "ce:surname": "Bunworasate", "ce:indexed-name": "Bunworasate U."}, "@seq": "19", "ce:initials": "U.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Bunworasate", "@auid": "6507403499", "author-url": "https://api.elsevier.com/content/author/author_id/6507403499", "ce:indexed-name": "Bunworasate U."}, {"ce:given-name": "Narcisa Sonia", "preferred-name": {"ce:given-name": "Narcisa Sonia", "ce:initials": "N.S.", "ce:surname": "Comia", "ce:indexed-name": "Comia N.S."}, "@seq": "20", "ce:initials": "N.S.", "@_fa": "true", "affiliation": {"@id": "101869722", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101869722"}, "ce:surname": "Comia", "@auid": "57199170199", "author-url": "https://api.elsevier.com/content/author/author_id/57199170199", "ce:indexed-name": "Comia N.S."}, {"ce:given-name": "Saengsuree", "preferred-name": {"ce:given-name": "Saengsuree", "ce:initials": "S.", "ce:surname": "Jootar", "ce:indexed-name": "Jootar S."}, "@seq": "21", "ce:initials": "S.", "@_fa": "true", "affiliation": {"@id": "60199578", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578"}, "ce:surname": "Jootar", "@auid": "7003833820", "author-url": "https://api.elsevier.com/content/author/author_id/7003833820", "ce:indexed-name": "Jootar S."}, {"ce:given-name": "Arry Harryanto", "preferred-name": {"ce:given-name": "Arry Harryanto", "ce:initials": "A.H.", "ce:surname": "Reksodiputro", "ce:indexed-name": "Reksodiputro A.H."}, "@seq": "22", "ce:initials": "A.H.", "@_fa": "true", "affiliation": {"@id": "60069378", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069378"}, "ce:surname": "Reksodiputro", "@auid": "6507867066", "author-url": "https://api.elsevier.com/content/author/author_id/6507867066", "ce:indexed-name": "Reksodiputro A.H."}, {"ce:given-name": "Priscilla B.", "preferred-name": {"ce:given-name": "Priscilla B.", "ce:initials": "P.B.", "ce:surname": "Caguioa", "ce:indexed-name": "Caguioa P.B."}, "@seq": "23", "ce:initials": "P.B.", "@_fa": "true", "affiliation": {"@id": "60071484", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071484"}, "ce:surname": "Caguioa", "@auid": "6506598676", "author-url": "https://api.elsevier.com/content/author/author_id/6506598676", "ce:indexed-name": "Caguioa P.B."}, {"ce:given-name": "Sung-Eun", "preferred-name": {"ce:given-name": "Sung Eun", "ce:initials": "S.E.", "ce:surname": "Lee", "ce:indexed-name": "Lee S.E."}, "@seq": "24", "ce:initials": "S.-E.", "@_fa": "true", "affiliation": {"@id": "60276990", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60276990"}, "ce:surname": "Lee", "@auid": "55156773300", "author-url": "https://api.elsevier.com/content/author/author_id/55156773300", "ce:indexed-name": "Lee S.-E."}, {"ce:given-name": "Dong-Wook", "preferred-name": {"ce:given-name": "Dong Wook", "ce:initials": "D.W.", "ce:surname": "Kim", "ce:indexed-name": "Kim D.W."}, "@seq": "25", "ce:initials": "D.-W.", "@_fa": "true", "affiliation": {"@id": "60276990", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60276990"}, "ce:surname": "Kim", "@auid": "57193414967", "author-url": "https://api.elsevier.com/content/author/author_id/57193414967", "ce:indexed-name": "Kim D.-W."}]}}}